Total Payments
$15,802
2024 Payments
$1,997
Companies
11
Transactions
54
Medicare Patients
2,576
Medicare Billing
$281,290
Payment Breakdown by Category
Research$9,309 (58.9%)
Travel$4,692 (29.7%)
Food & Beverage$1,790 (11.3%)
Education$11.75 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $9,309 | 5 | 58.9% |
| Travel and Lodging | $4,692 | 24 | 29.7% |
| Food and Beverage | $1,790 | 24 | 11.3% |
| Education | $11.75 | 1 | 0.1% |
Payments by Type
Research
$9,309
5 transactions
General
$6,493
49 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $8,198 | 3 | $0 (2024) |
| Novo Nordisk AS | $1,305 | 4 | $0 (2018) |
| F. Hoffmann-La Roche AG | $1,288 | 3 | $0 (2017) |
| Ferring Pharmaceuticals Inc. | $1,201 | 13 | $0 (2018) |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,111 | 2 | $0 (2018) |
| Allergan Inc. | $1,026 | 5 | $0 (2018) |
| AMAG Pharmaceuticals, Inc. | $945.19 | 7 | $0 (2017) |
| Eisai Inc. | $592.75 | 14 | $0 (2017) |
| Amgen Inc. | $121.87 | 1 | $0 (2019) |
| Ferring International Pharmascience Center US | $11.75 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,997 | 1 | Eli Lilly and Company ($1,997) |
| 2023 | $5,412 | 1 | Eli Lilly and Company ($5,412) |
| 2022 | $789.00 | 1 | Eli Lilly and Company ($789.00) |
| 2019 | $123.19 | 2 | Amgen Inc. ($121.87) |
| 2018 | $4,654 | 25 | Novo Nordisk AS ($1,305) |
| 2017 | $2,826 | 24 | F. Hoffmann-La Roche AG ($1,288) |
All Payment Transactions
54 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/12/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $1,997.00 | Research |
| Study: A STUDY OF LY3819469 IN PARTICIPANTS WITH ELEVATED LIPOPROTEIN(A) [LP(A)] | ||||||
| 05/08/2023 | Eli Lilly and Company | — | — | In-kind items and services | $5,412.41 | Research |
| Study: A STUDY OF LY3819469 IN PARTICIPANTS WITH ELEVATED LIPOPROTEIN(A) [LP(A)] | ||||||
| 08/23/2022 | Eli Lilly and Company | — | — | Cash or cash equivalent | $789.00 | Research |
| Study: THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | ||||||
| 09/16/2019 | KVK-Tech, Inc. | — | Food and Beverage | Cash or cash equivalent | $1.32 | General |
| 08/15/2019 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $121.87 | General |
| Category: Cardiology | ||||||
| 12/07/2018 | Allergan Inc. | — | Travel and Lodging | In-kind items and services | $445.95 | General |
| 12/07/2018 | Allergan Inc. | — | Travel and Lodging | In-kind items and services | $245.64 | General |
| 12/07/2018 | Allergan Inc. | — | Travel and Lodging | In-kind items and services | $178.99 | General |
| 12/07/2018 | Allergan Inc. | — | Food and Beverage | In-kind items and services | $96.99 | General |
| 12/07/2018 | Allergan Inc. | — | Travel and Lodging | In-kind items and services | $58.36 | General |
| 12/04/2018 | Ferring International Pharmascience Center US | — | Education | In-kind items and services | $11.75 | General |
| 09/07/2018 | Ferring Pharmaceuticals Inc. | — | Travel and Lodging | In-kind items and services | $97.06 | General |
| 09/07/2018 | Ferring Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $54.00 | General |
| 09/07/2018 | Ferring Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $44.99 | General |
| 09/07/2018 | Ferring Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $36.00 | General |
| 09/07/2018 | Ferring Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $26.99 | General |
| 09/07/2018 | Ferring Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $26.99 | General |
| 09/07/2018 | Ferring Pharmaceuticals Inc. | — | Travel and Lodging | In-kind items and services | $25.00 | General |
| 09/06/2018 | Ferring Pharmaceuticals Inc. | — | Travel and Lodging | In-kind items and services | $354.41 | General |
| 09/06/2018 | Ferring Pharmaceuticals Inc. | — | Travel and Lodging | In-kind items and services | $240.56 | General |
| 09/06/2018 | Ferring Pharmaceuticals Inc. | — | Travel and Lodging | In-kind items and services | $231.65 | General |
| 09/06/2018 | Ferring Pharmaceuticals Inc. | — | Travel and Lodging | In-kind items and services | $25.00 | General |
| 09/06/2018 | Ferring Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $19.63 | General |
| 09/06/2018 | Ferring Pharmaceuticals Inc. | — | Travel and Lodging | In-kind items and services | $18.53 | General |
| 04/11/2018 | Novo Nordisk AS | — | Travel and Lodging | In-kind items and services | $615.18 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A STUDY OF LY3819469 IN PARTICIPANTS WITH ELEVATED LIPOPROTEIN(A) [LP(A)] | Eli Lilly and Company | $7,409 | 2 |
| Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD | Takeda Pharmaceuticals U.S.A., Inc. | $1,111 | 2 |
| THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | Eli Lilly and Company | $789.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 585 | 1,179 | $107,430 | $67,486 |
| 2022 | 10 | 572 | 1,259 | $108,164 | $66,439 |
| 2021 | 11 | 611 | 1,181 | $110,432 | $68,541 |
| 2020 | 12 | 808 | 1,470 | $122,257 | $78,825 |
Total Patients
2,576
Total Services
5,089
Medicare Billing
$281,290
Procedure Codes
45
All Medicare Procedures & Services
45 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 153 | 411 | $80,965 | $52,275 | 64.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 27 | 36 | $4,860 | $3,324 | 68.4% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 62 | 133 | $5,320 | $2,190 | 41.2% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 27 | 28 | $3,495 | $2,117 | 60.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 104 | 254 | $2,500 | $2,108 | 84.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 24 | 26 | $2,548 | $1,688 | 66.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 23 | 26 | $1,665 | $1,084 | 65.1% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 30 | 31 | $1,085 | $937.44 | 86.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 17 | 75 | $2,625 | $768.27 | 29.3% |
| 81002 | Urinalysis, manual test | Office | 2023 | 89 | 129 | $1,139 | $439.89 | 38.6% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 16 | 17 | $816.00 | $428.91 | 52.6% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 13 | 13 | $412.00 | $124.08 | 30.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 162 | 428 | $84,316 | $54,349 | 64.5% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2022 | 43 | 43 | $5,160 | $3,021 | 58.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 28 | 32 | $4,320 | $2,924 | 67.7% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2022 | 49 | 100 | $4,000 | $1,644 | 41.1% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 46 | 46 | $1,610 | $1,318 | 81.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 20 | 118 | $4,103 | $1,233 | 30.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 104 | 234 | $1,404 | $693.42 | 49.4% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 15 | 17 | $1,105 | $671.26 | 60.7% |
| 81002 | Urinalysis, manual test | Office | 2022 | 90 | 129 | $1,030 | $443.10 | 43.0% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2022 | 15 | 112 | $1,116 | $142.53 | 12.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 159 | 430 | $84,710 | $54,828 | 64.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 44 | 51 | $6,885 | $4,714 | 68.5% |
| 90694 | Influenza virus vaccine, quadrivalent (aiiv4), inactivated, adjuvanted, preservative free, for injection into muscle, 0.5 ml dosage | Office | 2021 | 39 | 39 | $4,450 | $2,591 | 58.2% |
About Dr. Gigi Lefebvre, MD
Dr. Gigi Lefebvre, MD is a Family Medicine healthcare provider based in St Petersburg, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1801908074.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gigi Lefebvre, MD has received a total of $15,802 in payments from pharmaceutical and medical device companies, with $1,997 received in 2024. These payments were reported across 54 transactions from 11 companies. The most common payment nature is "" ($9,309).
As a Medicare-enrolled provider, Lefebvre has provided services to 2,576 Medicare beneficiaries, totaling 5,089 services with total Medicare billing of $281,290. Data is available for 4 years (2020–2023), covering 45 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location St Petersburg, FL
- Active Since 08/31/2006
- Last Updated 07/08/2007
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1801908074
Products in Payments
- Non-Covered Product (Drug) $1,288
- Actos (Drug) $1,111
- INTRAROSA (Drug) $945.19
- Repatha (Biological) $121.87
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in St Petersburg
Edward Braun, Md, MD
Family Medicine — Payments: $329,209
Family Medicine $329,209
Dr. Roxana Stoici, Md, MD
Family Medicine — Payments: $228,936
Family Medicine $228,936
Dr. Robert Wallace, Md, MD
Family Medicine — Payments: $151,311
Family Medicine $151,311
Dr. Frederic Guerrier, M.d, M.D
Family Medicine — Payments: $45,706
Family Medicine $45,706
Dr. Daniel Eckstein, M.d, M.D
Family Medicine — Payments: $10,665
Family Medicine $10,665
Dr. Kunal Amin, Md, MD
Family Medicine — Payments: $10,623
Family Medicine $10,623